Postinfectious IBS: What to Look For
Given the overall prevalence of irritable bowel syndrome, it is important for clinicians to be able to distinguish postinfectious irritable bowel syndrome from its other subtypes.
Given the overall prevalence of irritable bowel syndrome, it is important for clinicians to be able to distinguish postinfectious irritable bowel syndrome from its other subtypes.
Further research is warranted to understand the potential ways fecal microbiota transplantations may improve patients’ responses to immunotherapy.
In patients with IBD, management of immunosuppressive regimens, as well as safety and efficacy of vaccines, has raised many questions during the COVID-19 pandemic.
The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.